Cardiovascular DiseasesNCT07196917
Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China
An observational study of Cardiovascular Diseases and Respiratory Tract Diseases, run by Huazhong University of Science and Technology.
Trial summary
To further explore the application prospects of integrated Traditional Chinese and Western medicine in chronic disease prevention and control and health management, this study intends to establish a large, prospective, integrated Traditional Chinese and Western medicine cohort in Hubei Province. Read more about this study
- Who is it for?
- Ages 30 to 74 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases, Respiratory Tract Diseases, Cancer
- How many people
- 1,000,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2025to 31 Dec 2027
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 74 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Targeting urban and rural residents across multiple regions in Hubei Province, this study plans to recruit 1 million participants. Standardized protocols will be employed for baseline questionnaire surveys, physical examinations, and biological sample collection.
Who may be able to join
- Age: Participants aged 30 to 74 years
- Physical Functionality: Free from severe physical disabilities impacting mobility or communication, with preserved ability to comprehend and respond to study procedures
- Informed Consent: Capable of providing written informed consent voluntarily after receiving full study disclosure
Who cannot join
- Residents living in functional areas (e.g., work sheds, military units, student dormitories, nursing homes, etc.)
- Individuals unable to communicate normally
About this study
To further explore the application prospects of integrated Traditional Chinese and Western medicine in chronic disease prevention and control and health management, this study intends to establish a large, prospective, integrated Traditional Chinese and Western medicine cohort in Hubei Province. This study will conduct long-term follow-up and multi-dimensional data collection to systematically reveal the associations between Traditional Chinese Medicine (TCM) constitution types and chronic diseases, the aging process, and multi-morbidity, thereby developing an integrated health management strategy with local characteristics. This study will fill the current gap in systematic evidence linking TCM constitutions to the prevalence of modern diseases, providing a solid demographic and biological foundation for the integrated development of Traditional Chinese and Western medicine. It will also contribute to meeting the needs for early disease warning, early intervention, and personalized care under the "Healthy China" strategic goal.
- Conditions
- Cardiovascular Diseases, Respiratory Tract Diseases, Cancer, Endocrine System Diseases, Death
- Medical subject headings
- Cardiovascular Diseases, Respiratory Tract Diseases, Neoplasms, Endocrine System Diseases, Death
What is being measured
The primary outcome is the main question the study is designed to answer.
Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China
Measured: From enrollment to the 10-year follow-up
Incidence of major chronic diseases (coronary heart disease, stroke, diabetes, COPD, lung cancer, colorectal cancer, gastric cancer, liver cancer, and esophageal cancer)
Measured: From baseline (enrollment) to 10-year follow-up Measurement Tool: Standardized physician-adjudicated diagnosis based on ICD-10 codes, confirmed through hospital electronic medical records and disease registries
Secondary outcomes (1)
All-cause mortality
Time Frame: From baseline to 10-year follow-up Measurement Tool: Death registry linkage and hospital records Unit of Measure: Mortality rate per 1,000 person-years
Measured: From baseline to 10-year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start1 Oct 2025 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Huazhong University of Science and Technology
- Sponsor type
- University, hospital or other
- Collaborators
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei College of Traditional Chinese Medicine, Hubei Hospital of Traditional Chinese Medicine, Hubei Provincial Center for Disease Control and Prevention, Wuhan Center for Disease Control and Prevention
- Responsible party
- Principal investigator, Long Pin Pin, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07196917
- Sponsor's protocol ID
- 2023ZD0S09900)
- Status last verified
- Sep 2025
- First submitted
- 20 Sep 2025
- Last updated
- 2 Oct 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China
- ClinicalTrials.gov ID
- NCT07196917
- Acronym / sponsor ID
- 2023ZD0S09900)
- Conditions
- Cardiovascular Diseases, Respiratory Tract Diseases, Cancer, Endocrine System Diseases, Death
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,000,000 participants (estimated)
- Lead sponsor
- Huazhong University of Science and TechnologyUniversity, hospital or other
- Collaborators
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei College of Traditional Chinese Medicine, Hubei Hospital of Traditional Chinese Medicine, Hubei Provincial Center for Disease Control and Prevention, Wuhan Center for Disease Control and Prevention
- Study start
- 1 Oct 2025 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To further explore the application prospects of integrated Traditional Chinese and Western medicine in chronic disease prevention and control and health management, this study intends to establish a large, prospective, integrated Traditional Chinese and Western medicine cohort in Hubei Province. This study will conduct long-term follow-up and multi-dimensional data collection to systematically reveal the associations between Traditional Chinese Medicine (TCM) constitution types and chronic diseases, the aging process, and multi-morbidity, thereby developing an integrated health management strategy with local characteristics. This study will fill the current gap in systematic evidence linking TCM constitutions to the prevalence of modern diseases, providing a solid demographic and biological foundation for the integrated development of Traditional Chinese and Western medicine. It will also contribute to meeting the needs for early disease warning, early intervention, and personalized care under the "Healthy China" strategic goal.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 30 to 74 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Targeting urban and rural residents across multiple regions in Hubei Province, this study plans to recruit 1 million participants. Standardized protocols will be employed for baseline questionnaire surveys, physical examinations, and biological sample collection.
Key inclusion criteria (3 listed)
- Age: Participants aged 30 to 74 years
- Physical Functionality: Free from severe physical disabilities impacting mobility or communication, with preserved ability to comprehend and respond to study procedures
- Informed Consent: Capable of providing written informed consent voluntarily after receiving full study disclosure
Key exclusion criteria (2 listed)
- Residents living in functional areas (e.g., work sheds, military units, student dormitories, nursing homes, etc.)
- Individuals unable to communicate normally
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China
Time frame: From enrollment to the 10-year follow-up
Incidence of major chronic diseases (coronary heart disease, stroke, diabetes, COPD, lung cancer, colorectal cancer, gastric cancer, liver cancer, and esophageal cancer)
Time frame: From baseline (enrollment) to 10-year follow-up Measurement Tool: Standardized physician-adjudicated diagnosis based on ICD-10 codes, confirmed through hospital electronic medical records and disease registries
1 secondary outcome
All-cause mortality
Time frame: From baseline to 10-year follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2025.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Respiratory Tract Diseases, run by Huazhong University of Science and Technology.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China (time frame: From enrollment to the 10-year follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.